Prognostic significance of concentric left ventricular hypertrophy at peritoneal dialysis initiation

Misato Tomura1, Yoshifumi Hamasaki2, Yohei Komaru1

  • 1Hemodialysis and Apheresis, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo, Tokyo, Japan.

BMC Nephrology
|April 17, 2021
PubMed

Insights

Concentric left ventricular hypertrophy (cLVH) at peritoneal dialysis (PD) initiation is linked to reduced survival and major adverse cardiovascular events (MACE). Early identification of cLVH may help manage high-risk patients on PD.

Area of Science:

  • Nephrology
  • Cardiology
  • Clinical Medicine

Background:

  • Concentric left ventricular hypertrophy (cLVH) is a common finding in patients on maintenance dialysis, including peritoneal dialysis (PD).
  • The prognostic significance of cLVH at the initiation of PD remains incompletely understood.
  • This study investigates the impact of cLVH on patient survival and major adverse cardiovascular events (MACE) in PD patients.

Purpose of the Study:

  • To determine the association between cLVH at PD initiation and patient survival.
  • To assess the relationship between cLVH at PD initiation and the occurrence of MACE.
  • To identify cLVH as a potential risk factor for adverse outcomes in PD patients.

Main Methods:

  • A retrospective cohort study involving 131 patients undergoing PD.
  • Echocardiography was performed at PD initiation to assess left ventricular mass index and relative wall thickness for cLVH diagnosis.
  • Cox regression analysis was used to evaluate the association between cLVH and patient prognosis.

Main Results:

  • Concentric LVH was present in 22% of patients at PD initiation.
  • Patients with cLVH exhibited significantly reduced survival, MACE-free survival, and PD continuation rates.
  • cLVH was an independent risk factor for mortality in all patients and associated with mortality and MACE in elderly patients (>65 years).
  • Lower serum albumin levels at PD initiation were correlated with cLVH.

Conclusions:

  • cLVH at PD initiation is independently associated with reduced survival in all patients and with both survival and MACE in elderly patients.
  • Assessing LV geometry at PD initiation can help identify high-risk individuals.
  • Further research with larger cohorts is needed to confirm these findings and explore interventions, such as nutritional support, to improve outcomes.
Abstract

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
154
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
119
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
121
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
104
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications01:25

Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications

Peritoneal dialysis (PD) is a medical process that removes waste products and excess fluid from the body using the peritoneal membrane as a natural filter.Peritoneal Dialysis MethodsSeveral methods can be used for peritoneal dialysis, including Acute Intermittent Peritoneal Dialysis, Continuous Ambulatory Peritoneal Dialysis, and Automated Peritoneal Dialysis, also known as Continuous Cyclic Peritoneal Dialysis.Acute Intermittent Peritoneal Dialysis (AIPD) is used for patients with uremic...
200
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.1K